Arrowhead's CEO Blames Rival's Execution As His Own Launch Faces A Reimbursement Bottleneck
Management defined launch speed through prescriptions, prescribers and coverage, while saying sales guidance was premature.
Arrowhead Pharmaceuticals, which develops gene-silencing medicines, is preparing for a rapid expansion of REDEMPLO despite its own reimbursement bottleneck, President and Chief Executive Officer Dr. Chris Anzalone said on Thursday's earnings call. He blamed rival Ionis's launch difficulties on execution, while analysts questioned how quickly Arrowhead's growing prescription count would translate into sales.
Prescriptions Still Need Paid Shipments
Anzalone attributed Ionis's problems to "missteps in communications and missteps in commercial execution" and said they had not changed Arrowhead's expectations for severe hypertriglyceridemia—very high blood triglyceride levels.
Arrowhead faces a similar practical task: getting insurers to pay once doctors prescribe its medicine. Anzalone called that process "still a choke point" and acknowledged substantial work remained.
REDEMPLO's initial launch, into the rare disease familial chylomicronemia syndrome, began about 11 months ago. New-patient prescriptions increased 63% during the fiscal fourth quarter, reaching 950 at September 30. The cumulative count subsequently exceeded 1,250.
Distinct prescribers increased from more than 640 at September 30 to more than 860 by the first week of November. Approximately 27% had prescribed for multiple patients. Coverage now spans more than 160 million U.S. lives, meaning eligible patients have a reimbursement pathway under insurer criteria.
Those measures sit alongside approximately $6.6 million in net product revenue during Arrowhead's first commercial-sales year. Written prescriptions must pass through benefit checks, office support and insurer authorization before becoming paid treatment.
A Rapid Launch, Without Sales Guidance
An analyst asked whether management's repeated promise of a rapid launch referred to prescriptions rather than revenue. Insurance coverage, new-patient prescriptions and the breadth of prescribing doctors would be Arrowhead's early reporting measures, according to Andy Davis, Head of the Global Cardiometabolic Franchise and Senior Vice President.
Anzalone said revenue and profitability would ultimately determine commercial success, but early sales would not fully capture progress while coverage and provider outreach were being established. Asked for sales guidance, he replied, "it's just too early to provide guidance." He said Arrowhead needed the FDA's final label and more experience with insurers.
Davis defended the annual U.S. wholesale price of $45,000 per patient. Arrowhead intends to keep that price across both uses if the broader indication wins approval. He said pre-approval discussions with insurers had produced no pushback on the pricing range.
Arrowhead already offers a bridge program and patient assistance to start treatment while coverage is arranged. Davis expects a bridge program for the expanded use as well, if approved; converting patients to paid therapy and keeping them on treatment remain priorities.
Clinical Promise Meets A Larger Market
The expansion rests on a pooled trial analysis showing a 78% reduction in acute pancreatitis events versus placebo. Among patients with a prior pancreatitis history, the reduction was 91%.
Arrowhead submitted its expanded-use FDA application on November 2. Management estimates an initial high-risk population of approximately 1 million U.S. patients and has identified more than 20,000 healthcare professionals as likely treaters. Its expanded sales team is largely in place.
Davis estimated that around 200,000 U.S. patients have experienced pancreatitis associated with high triglycerides. He expects reaching the broader treatment population to take more time and depend on favorable insurer policies.
REDEMPLO is Arrowhead's first commercial product, approved alongside diet for adults with familial chylomicronemia syndrome. Building a business around it now requires the insurer access and prescribing relationships needed to serve a much larger population.
Arrowhead is preparing for a potential U.S. launch in severe hypertriglyceridemia in the second calendar quarter of 2027, subject to FDA approval.
Sources
- Arrowhead Pharmaceuticals Presents Plozasiran Data Highlighting Sustained Triglyceride Reductions and Reduced Acute Pancreatitis Rates – Company Announcement - FT.com — Financial Times
- Is Arrowhead Pharmaceuticals (ARWR) Worth Its Price After UK Approval? — Yahoo Finance
- Arrowhead Pharmaceuticals Reports 2026 Fiscal Year-End Results — businesswire.com